CA2690772A1 - Novel peptide amphiphiles having improved solubility and methods of using same - Google Patents
Novel peptide amphiphiles having improved solubility and methods of using same Download PDFInfo
- Publication number
- CA2690772A1 CA2690772A1 CA2690772A CA2690772A CA2690772A1 CA 2690772 A1 CA2690772 A1 CA 2690772A1 CA 2690772 A CA2690772 A CA 2690772A CA 2690772 A CA2690772 A CA 2690772A CA 2690772 A1 CA2690772 A1 CA 2690772A1
- Authority
- CA
- Canada
- Prior art keywords
- peptide
- ala
- val
- seq
- peptide amphiphile
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 171
- 238000000034 method Methods 0.000 title claims description 56
- 230000001976 improved effect Effects 0.000 title abstract description 15
- OGQYPPBGSLZBEG-UHFFFAOYSA-N dimethyl(dioctadecyl)azanium Chemical compound CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC OGQYPPBGSLZBEG-UHFFFAOYSA-N 0.000 claims abstract description 76
- 239000000203 mixture Substances 0.000 claims abstract description 49
- 239000000499 gel Substances 0.000 claims abstract description 39
- 239000002121 nanofiber Substances 0.000 claims description 33
- 230000012010 growth Effects 0.000 claims description 31
- 210000005036 nerve Anatomy 0.000 claims description 26
- 238000011161 development Methods 0.000 claims description 24
- 230000018109 developmental process Effects 0.000 claims description 24
- 210000002569 neuron Anatomy 0.000 claims description 24
- 235000001014 amino acid Nutrition 0.000 claims description 23
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 22
- 150000001413 amino acids Chemical class 0.000 claims description 22
- 125000000539 amino acid group Chemical group 0.000 claims description 21
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 19
- 210000005155 neural progenitor cell Anatomy 0.000 claims description 18
- 210000004027 cell Anatomy 0.000 claims description 16
- UHBYWPGGCSDKFX-VKHMYHEASA-N gamma-carboxy-L-glutamic acid Chemical compound OC(=O)[C@@H](N)CC(C(O)=O)C(O)=O UHBYWPGGCSDKFX-VKHMYHEASA-N 0.000 claims description 14
- 230000007514 neuronal growth Effects 0.000 claims description 14
- 235000003704 aspartic acid Nutrition 0.000 claims description 13
- 230000003376 axonal effect Effects 0.000 claims description 13
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 13
- 239000000693 micelle Substances 0.000 claims description 13
- 230000015572 biosynthetic process Effects 0.000 claims description 11
- 210000000278 spinal cord Anatomy 0.000 claims description 11
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 10
- 235000013922 glutamic acid Nutrition 0.000 claims description 10
- 239000004220 glutamic acid Substances 0.000 claims description 10
- 230000004069 differentiation Effects 0.000 claims description 9
- 239000000835 fiber Substances 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 8
- 230000002378 acidificating effect Effects 0.000 claims description 8
- 239000007864 aqueous solution Substances 0.000 claims description 8
- 239000011159 matrix material Substances 0.000 claims description 8
- 230000002829 reductive effect Effects 0.000 claims description 8
- OYIFNHCXNCRBQI-UHFFFAOYSA-N 2-aminoadipic acid Chemical compound OC(=O)C(N)CCCC(O)=O OYIFNHCXNCRBQI-UHFFFAOYSA-N 0.000 claims description 7
- 206010018341 Gliosis Diseases 0.000 claims description 7
- 208000037875 astrocytosis Diseases 0.000 claims description 7
- 230000007341 astrogliosis Effects 0.000 claims description 7
- 210000003061 neural cell Anatomy 0.000 claims description 7
- JUQLUIFNNFIIKC-UHFFFAOYSA-N 2-aminopimelic acid Chemical compound OC(=O)C(N)CCCCC(O)=O JUQLUIFNNFIIKC-UHFFFAOYSA-N 0.000 claims description 6
- JINBYESILADKFW-UHFFFAOYSA-N aminomalonic acid Chemical compound OC(=O)C(N)C(O)=O JINBYESILADKFW-UHFFFAOYSA-N 0.000 claims description 6
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 6
- 230000004962 physiological condition Effects 0.000 claims description 6
- 238000011069 regeneration method Methods 0.000 claims description 6
- 208000020431 spinal cord injury Diseases 0.000 claims description 6
- 230000008467 tissue growth Effects 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 230000001174 ascending effect Effects 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 230000005764 inhibitory process Effects 0.000 claims description 5
- 210000002161 motor neuron Anatomy 0.000 claims description 5
- 230000008929 regeneration Effects 0.000 claims description 5
- 230000001953 sensory effect Effects 0.000 claims description 5
- 208000028389 Nerve injury Diseases 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 239000003966 growth inhibitor Substances 0.000 claims description 4
- 238000007913 intrathecal administration Methods 0.000 claims description 4
- 230000008764 nerve damage Effects 0.000 claims description 4
- 238000010647 peptide synthesis reaction Methods 0.000 claims description 4
- 210000001044 sensory neuron Anatomy 0.000 claims description 4
- 210000000130 stem cell Anatomy 0.000 claims description 4
- 230000000472 traumatic effect Effects 0.000 claims description 4
- 108010025020 Nerve Growth Factor Proteins 0.000 claims description 3
- 102000007072 Nerve Growth Factors Human genes 0.000 claims description 3
- 235000021314 Palmitic acid Nutrition 0.000 claims description 3
- 210000004899 c-terminal region Anatomy 0.000 claims description 3
- 230000006378 damage Effects 0.000 claims description 3
- 238000011068 loading method Methods 0.000 claims description 3
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims description 3
- 210000002241 neurite Anatomy 0.000 claims description 3
- 239000003900 neurotrophic factor Substances 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 239000007790 solid phase Substances 0.000 claims description 3
- 239000000758 substrate Substances 0.000 claims description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 2
- 239000012736 aqueous medium Substances 0.000 claims description 2
- 239000005667 attractant Substances 0.000 claims description 2
- 230000031902 chemoattractant activity Effects 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 230000001737 promoting effect Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 108010016626 Dipeptides Proteins 0.000 claims 1
- WYNCHZVNFNFDNH-UHFFFAOYSA-N Oxazolidine Chemical compound C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000002952 polymeric resin Substances 0.000 claims 1
- 229920003002 synthetic resin Polymers 0.000 claims 1
- 238000001879 gelation Methods 0.000 abstract description 13
- 238000000746 purification Methods 0.000 abstract description 13
- 210000003169 central nervous system Anatomy 0.000 abstract description 9
- 230000001965 increasing effect Effects 0.000 abstract description 6
- 239000012062 aqueous buffer Substances 0.000 abstract description 5
- 238000001727 in vivo Methods 0.000 abstract description 5
- 210000001519 tissue Anatomy 0.000 description 40
- 239000000463 material Substances 0.000 description 23
- 239000000243 solution Substances 0.000 description 23
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 21
- 238000001338 self-assembly Methods 0.000 description 18
- 125000003275 alpha amino acid group Chemical group 0.000 description 16
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 238000004128 high performance liquid chromatography Methods 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- XQQUSYWGKLRJRA-RABCQHRBSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s,3s)-2-amino-3-methylpentanoyl]amino]hexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-3-methylbutanoic acid Chemical group CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O XQQUSYWGKLRJRA-RABCQHRBSA-N 0.000 description 8
- 238000013461 design Methods 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 230000024245 cell differentiation Effects 0.000 description 7
- 230000008878 coupling Effects 0.000 description 7
- 238000010168 coupling process Methods 0.000 description 7
- 238000005859 coupling reaction Methods 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 239000011347 resin Substances 0.000 description 7
- 229920005989 resin Polymers 0.000 description 7
- YUJLIIRMIAGMCQ-CIUDSAMLSA-N Ser-Leu-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YUJLIIRMIAGMCQ-CIUDSAMLSA-N 0.000 description 6
- 230000027455 binding Effects 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 108010088381 isoleucyl-lysyl-valyl-alanyl-valine Proteins 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 231100000241 scar Toxicity 0.000 description 6
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- VWPJQIHBBOJWDN-DCAQKATOSA-N Lys-Val-Ala Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(O)=O VWPJQIHBBOJWDN-DCAQKATOSA-N 0.000 description 5
- 239000000908 ammonium hydroxide Substances 0.000 description 5
- 235000011114 ammonium hydroxide Nutrition 0.000 description 5
- 229940043379 ammonium hydroxide Drugs 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 230000002209 hydrophobic effect Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000002086 nanomaterial Substances 0.000 description 4
- 230000004936 stimulating effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000009772 tissue formation Effects 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 3
- 230000000975 bioactive effect Effects 0.000 description 3
- 239000012620 biological material Substances 0.000 description 3
- -1 cells Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 238000010511 deprotection reaction Methods 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 229910001873 dinitrogen Inorganic materials 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 230000001172 regenerating effect Effects 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- ZGYICYBLPGRURT-UHFFFAOYSA-N tri(propan-2-yl)silicon Chemical compound CC(C)[Si](C(C)C)C(C)C ZGYICYBLPGRURT-UHFFFAOYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- LSLXWOCIIFUZCQ-SRVKXCTJSA-N (2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methyl-1-oxobutyl]amino]-3-methyl-1-oxobutyl]amino]-3-methylbutanoic acid Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(O)=O LSLXWOCIIFUZCQ-SRVKXCTJSA-N 0.000 description 2
- YLTKNGYYPIWKHZ-ACZMJKKPSA-N Ala-Ala-Glu Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCC(O)=O YLTKNGYYPIWKHZ-ACZMJKKPSA-N 0.000 description 2
- RLMISHABBKUNFO-WHFBIAKZSA-N Ala-Ala-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O RLMISHABBKUNFO-WHFBIAKZSA-N 0.000 description 2
- CKLJMWTZIZZHCS-UHFFFAOYSA-N Aspartic acid Chemical compound OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241001432959 Chernes Species 0.000 description 2
- XTZDZAXYPDISRR-MNXVOIDGSA-N Glu-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)O)N XTZDZAXYPDISRR-MNXVOIDGSA-N 0.000 description 2
- 102000009465 Growth Factor Receptors Human genes 0.000 description 2
- 108010009202 Growth Factor Receptors Proteins 0.000 description 2
- 108010085895 Laminin Proteins 0.000 description 2
- YUGVQABRIJXYNQ-CIUDSAMLSA-N Leu-Ala-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O YUGVQABRIJXYNQ-CIUDSAMLSA-N 0.000 description 2
- YUGVQABRIJXYNQ-UHFFFAOYSA-N Leu-Ala-Ala Natural products CC(C)CC(N)C(=O)NC(C)C(=O)NC(C)C(O)=O YUGVQABRIJXYNQ-UHFFFAOYSA-N 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- QRZVUAAKNRHEOP-GUBZILKMSA-N Val-Ala-Val Chemical compound [H]N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O QRZVUAAKNRHEOP-GUBZILKMSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000021736 acetylation Effects 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 108010076324 alanyl-glycyl-glycine Proteins 0.000 description 2
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 2
- 230000003190 augmentative effect Effects 0.000 description 2
- 210000003050 axon Anatomy 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 2
- 230000025611 cell-substrate adhesion Effects 0.000 description 2
- 230000021617 central nervous system development Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000001553 co-assembly Methods 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Natural products NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000029226 lipidation Effects 0.000 description 2
- 150000002634 lipophilic molecules Chemical class 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 230000001272 neurogenic effect Effects 0.000 description 2
- 230000014511 neuron projection development Effects 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000002390 rotary evaporation Methods 0.000 description 2
- 230000036573 scar formation Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 108010021199 valyl-valyl-valine Proteins 0.000 description 2
- 108010073969 valyllysine Proteins 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- RVLOMLVNNBWRSR-KNIFDHDWSA-N (2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O RVLOMLVNNBWRSR-KNIFDHDWSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- WNTGYJSOUMFZEP-UHFFFAOYSA-N 2-(4-chloro-2-methylphenoxy)propanoic acid Chemical compound OC(=O)C(C)OC1=CC=C(Cl)C=C1C WNTGYJSOUMFZEP-UHFFFAOYSA-N 0.000 description 1
- FZTIWOBQQYPTCJ-UHFFFAOYSA-N 4-[4-(4-carboxyphenyl)phenyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C1=CC=C(C=2C=CC(=CC=2)C(O)=O)C=C1 FZTIWOBQQYPTCJ-UHFFFAOYSA-N 0.000 description 1
- CCYFIZIEAFRYKT-LJQANCHMSA-N 9h-fluoren-9-ylmethyl n-[(2s)-3-methyl-1-oxobutan-2-yl]carbamate Chemical compound C1=CC=C2C(COC(=O)N[C@@H](C(C)C)C=O)C3=CC=CC=C3C2=C1 CCYFIZIEAFRYKT-LJQANCHMSA-N 0.000 description 1
- 108010060263 Adenosine A1 Receptor Proteins 0.000 description 1
- 102000030814 Adenosine A1 receptor Human genes 0.000 description 1
- YYSWCHMLFJLLBJ-ZLUOBGJFSA-N Ala-Ala-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YYSWCHMLFJLLBJ-ZLUOBGJFSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 241001535291 Analges Species 0.000 description 1
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- NLCZGISONIGRQP-DCAQKATOSA-N Cys-Arg-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CS)N NLCZGISONIGRQP-DCAQKATOSA-N 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- KOSRFJWDECSPRO-WDSKDSINSA-N Glu-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(O)=O KOSRFJWDECSPRO-WDSKDSINSA-N 0.000 description 1
- YOBGUCWZPXJHTN-BQBZGAKWSA-N Gly-Ser-Arg Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCN=C(N)N YOBGUCWZPXJHTN-BQBZGAKWSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 102100022746 Laminin subunit alpha-1 Human genes 0.000 description 1
- 101710200522 Laminin subunit alpha-1 Proteins 0.000 description 1
- WIDZHJTYKYBLSR-DCAQKATOSA-N Leu-Glu-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O WIDZHJTYKYBLSR-DCAQKATOSA-N 0.000 description 1
- YOKVEHGYYQEQOP-QWRGUYRKSA-N Leu-Leu-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O YOKVEHGYYQEQOP-QWRGUYRKSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 108010028921 Lipopeptides Proteins 0.000 description 1
- YQAIUOWPSUOINN-IUCAKERBSA-N Lys-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCCN YQAIUOWPSUOINN-IUCAKERBSA-N 0.000 description 1
- 239000002616 MRI contrast agent Substances 0.000 description 1
- 108060003100 Magainin Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 101100015391 Mus musculus Ralgds gene Proteins 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- NFDYGNFETJVMSE-BQBZGAKWSA-N Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CO NFDYGNFETJVMSE-BQBZGAKWSA-N 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- IJBTVYLICXHDRI-UHFFFAOYSA-N Val-Ala-Ala Natural products CC(C)C(N)C(=O)NC(C)C(=O)NC(C)C(O)=O IJBTVYLICXHDRI-UHFFFAOYSA-N 0.000 description 1
- DEGUERSKQBRZMZ-FXQIFTODSA-N Val-Ser-Ala Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O DEGUERSKQBRZMZ-FXQIFTODSA-N 0.000 description 1
- KRNYOVHEKOBTEF-YUMQZZPRSA-N Val-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C(C)C)C(O)=O KRNYOVHEKOBTEF-YUMQZZPRSA-N 0.000 description 1
- IWADHXDXSQONEL-GUBZILKMSA-N Val-Val-Ala Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(O)=O IWADHXDXSQONEL-GUBZILKMSA-N 0.000 description 1
- 239000003875 Wang resin Substances 0.000 description 1
- NERFNHBZJXXFGY-UHFFFAOYSA-N [4-[(4-methylphenyl)methoxy]phenyl]methanol Chemical compound C1=CC(C)=CC=C1COC1=CC=C(CO)C=C1 NERFNHBZJXXFGY-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 239000003012 bilayer membrane Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000003592 biomimetic effect Effects 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000002041 carbon nanotube Substances 0.000 description 1
- 229910021393 carbon nanotube Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000002408 directed self-assembly Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000004146 energy storage Methods 0.000 description 1
- 230000001787 epileptiform Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthrene Natural products C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 108010055341 glutamyl-glutamic acid Proteins 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 150000001261 hydroxy acids Chemical class 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 108010073093 leucyl-glycyl-glycyl-glycine Proteins 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 108010017391 lysylvaline Proteins 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002062 molecular scaffold Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000003518 presynaptic effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 description 1
- 229960004134 propofol Drugs 0.000 description 1
- 239000013014 purified material Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000002278 reconstructive surgery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000007261 regionalization Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 108010021889 valylvaline Proteins 0.000 description 1
- 239000003190 viscoelastic substance Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91228907P | 2007-04-17 | 2007-04-17 | |
| US60/912,289 | 2007-04-17 | ||
| US12/104,407 US8076295B2 (en) | 2007-04-17 | 2008-04-16 | Peptide amphiphiles having improved solubility and methods of using same |
| US12/104,407 | 2008-04-16 | ||
| PCT/US2008/060559 WO2008131052A2 (en) | 2007-04-17 | 2008-04-17 | Novel peptide amphiphiles having improved solubility and methods of using same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2690772A1 true CA2690772A1 (en) | 2008-10-30 |
Family
ID=39876156
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2690772A Abandoned CA2690772A1 (en) | 2007-04-17 | 2008-04-17 | Novel peptide amphiphiles having improved solubility and methods of using same |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8076295B2 (OSRAM) |
| EP (1) | EP2146734A4 (OSRAM) |
| JP (1) | JP2010524958A (OSRAM) |
| KR (1) | KR20100021567A (OSRAM) |
| CN (1) | CN101848722A (OSRAM) |
| AU (1) | AU2008242940A1 (OSRAM) |
| CA (1) | CA2690772A1 (OSRAM) |
| WO (1) | WO2008131052A2 (OSRAM) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003215280A1 (en) * | 2002-02-15 | 2003-09-09 | Northwestern University | Self-assembly of peptide-amphiphile nanofibers under physiological conditions |
| US7554021B2 (en) * | 2002-11-12 | 2009-06-30 | Northwestern University | Composition and method for self-assembly and mineralization of peptide amphiphiles |
| EP1696945B1 (en) | 2003-12-05 | 2012-01-18 | Northwestern University | Self-assembling peptide amphiphiles and related methods for growth factor delivery |
| MX2007008826A (es) * | 2005-01-21 | 2007-11-15 | Univ Northwestern | Metodos y composiciones para encapsulacion de celulas. |
| US8076295B2 (en) | 2007-04-17 | 2011-12-13 | Nanotope, Inc. | Peptide amphiphiles having improved solubility and methods of using same |
| MX2011010780A (es) * | 2009-04-13 | 2011-10-28 | Univ Northwestern | Andamios novedosos basados en peptido para la regeneracion de cartilagos y metodos para su uso. |
| ES2574056T3 (es) * | 2010-03-31 | 2016-06-14 | Agency For Science, Technology And Research | Péptido/peptoide anfifílico lineal e hidrogel que comprende el mismo |
| US8546338B2 (en) | 2010-12-08 | 2013-10-01 | Johnson & Johnson Consumer Companies, Inc. | Self-assembling hydrogels based on dicephalic peptide amphiphiles |
| SG11201404648PA (en) * | 2012-02-15 | 2014-09-26 | Aileron Therapeutics Inc | Peptidomimetic macrocycles |
| KR101501436B1 (ko) * | 2013-02-14 | 2015-03-18 | 주식회사 나이벡 | 생리활성 펩타이드가 자기회합된 젤 형태의 지지체 및 그 제조방법 |
| CN108289926A (zh) | 2015-10-14 | 2018-07-17 | 西北大学 | 用于生长因子递送和骨再生的纳米纤维糊剂 |
| CN105694030B (zh) * | 2016-04-05 | 2018-01-26 | 中国科学院化学研究所 | 一种寡聚氨基酸与海藻酸钠复合的杂化抗菌水凝胶 |
| US10738338B2 (en) | 2016-10-18 | 2020-08-11 | The Research Foundation for the State University | Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate |
| WO2018075885A1 (en) | 2016-10-21 | 2018-04-26 | Northwestern University | Anti-microbial supramolecular structures |
| WO2019036631A1 (en) | 2017-08-18 | 2019-02-21 | The Johns Hopkins University | SUPRAMOLECULAR FILAMENT ASSEMBLIES FOR THE PURIFICATION OF PROTEINS |
| CN108070021B (zh) * | 2017-12-27 | 2021-06-15 | 中南民族大学 | 可组装成高度有序纳米纤维的小分子肽及组装构建高度有序纳米纤维的方法 |
| WO2020154631A1 (en) * | 2019-01-24 | 2020-07-30 | Northwestern University | Dynamics within supramolecular 1kvav matrices enhance functional maturation of human ipscs-der1ved neurons and regeneration |
| CN113396154A (zh) * | 2019-02-08 | 2021-09-14 | 新加坡科技研究局 | 自组装短两亲性肽以及相关的方法和用途 |
| US12214076B2 (en) | 2019-02-18 | 2025-02-04 | Northwestern University | Drug delivery vehicles for atherosclerosis nanomedicine |
| CN114555625B (zh) * | 2019-07-02 | 2025-02-25 | 塔夫茨学院托管部 | 用于将剂递送至细胞和组织中的新型肽、组合物和方法 |
| US11998589B2 (en) | 2020-07-13 | 2024-06-04 | Northwestern University | PEGylated peptide amphiphile nanofibers and methods of use |
| US12247063B2 (en) | 2020-07-13 | 2025-03-11 | Northwestern University | Cell surface modification by coating with peptide amphiphiles (PAs) |
| US12116461B2 (en) | 2020-08-21 | 2024-10-15 | Northwestern University | Host-guest interactions for pa superstructure formation |
| EP4384532A4 (en) * | 2021-08-09 | 2025-07-02 | Gel4Med Inc | SELF-ASSEMBLING AMPHIPHILIC PEPTIDE HYDROGELS FOR THE TREATMENT OF NERVE INJURY |
Family Cites Families (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4554101A (en) * | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| US5130123A (en) * | 1981-03-04 | 1992-07-14 | The University Of Melbourne | Dentifrice |
| US4930077A (en) * | 1987-04-06 | 1990-05-29 | Fan David P | Information processing expert system for text analysis and predicting public opinion based information available to the public |
| US5128319A (en) * | 1987-08-28 | 1992-07-07 | Board Of Regents, The University Of Texas System | Prophylaxis and therapy of acquired immunodeficiency syndrome |
| GB8812214D0 (en) * | 1988-05-24 | 1988-06-29 | Hoffmann La Roche | Use of peptide from circumsporozoite protein of p falciparum as universally recognized t-cell epitope |
| US5223409A (en) * | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| JPH0399096A (ja) | 1989-09-11 | 1991-04-24 | Agency Of Ind Science & Technol | 短繊維型螺旋状分子会合体の長さ制御方法 |
| DE4026978A1 (de) * | 1990-08-25 | 1992-02-27 | Bayer Ag | Auf traegern angebrachte ein- oder mehrlagige schichtelemente und ihre herstellung |
| CA2109085C (en) * | 1991-04-25 | 2003-03-11 | Keith E. Dionne | Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products |
| US5580563A (en) | 1992-05-01 | 1996-12-03 | Tam; James P. | Multiple antigen peptide system having adjuvant properties, vaccines prepared therefrom and methods of use thereof |
| GB9215780D0 (en) | 1992-07-24 | 1992-09-09 | Univ London Pharmacy | Peptide compounds |
| US5670483A (en) * | 1992-12-28 | 1997-09-23 | Massachusetts Insititute Of Technology | Stable macroscopic membranes formed by self-assembly of amphiphilic peptides and uses therefor |
| US5955343A (en) * | 1992-12-28 | 1999-09-21 | Massachusetts Institute Of Technology | Stable macroscopic membranes formed by self-assembly of amphiphilic peptides and uses therefor |
| SE9402531L (sv) | 1994-07-19 | 1996-01-20 | Medicarb Ab | Sårläkningsmedel |
| US5843780A (en) * | 1995-01-20 | 1998-12-01 | Wisconsin Alumni Research Foundation | Primate embryonic stem cells |
| US6410690B1 (en) * | 1995-06-07 | 2002-06-25 | Medarex, Inc. | Therapeutic compounds comprised of anti-Fc receptor antibodies |
| CA2228118A1 (en) * | 1995-07-28 | 1997-02-13 | Focal, Inc. | Multiblock biodegradable hydrogels for use as controlled release agents for drugs delivery and tissue treatments agents |
| US5622699A (en) * | 1995-09-11 | 1997-04-22 | La Jolla Cancer Research Foundation | Method of identifying molecules that home to a selected organ in vivo |
| FR2739860B1 (fr) | 1995-10-17 | 1998-01-02 | Coletica | Complexes amphiphiles, procede pour leur preparation et compositions en renfermant |
| SE9504347D0 (sv) | 1995-12-01 | 1995-12-01 | Boerje Sellergren | Surface modification technique |
| US6051272A (en) * | 1996-03-15 | 2000-04-18 | The Board Of Trustees Of The University Of Illinois | Method for synthesizing organoapatites on to surgical metal alloys |
| US5733868A (en) * | 1996-04-16 | 1998-03-31 | Depuy Orthopaedics, Inc. | Poly(amino acid) adhesive tissue grafts |
| WO1997047695A1 (en) * | 1996-06-12 | 1997-12-18 | Hoechst Trespaphan Gmbh | Transparent barrier coatings exhibiting reduced thin film interference |
| US6085206A (en) * | 1996-06-20 | 2000-07-04 | Microsoft Corporation | Method and system for verifying accuracy of spelling and grammatical composition of a document |
| US5993541A (en) * | 1996-07-31 | 1999-11-30 | Geo Centers Inc | Process for nucleation of ceramics and product thereof |
| US6096863A (en) * | 1996-08-23 | 2000-08-01 | Regents Of The University Of Minnesota | Self-assembling amphiphiles for construction of peptide secondary structures |
| US6458924B2 (en) * | 1996-08-30 | 2002-10-01 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
| BR9806793A (pt) * | 1997-01-22 | 2000-05-16 | Univ Texas | Processos e composições de fator tissular para coagulação e tratamento de tumores. |
| US6331406B1 (en) * | 1997-03-31 | 2001-12-18 | The John Hopkins University School Of Medicine | Human enbryonic germ cell and methods of use |
| DE19882746T1 (de) | 1997-04-03 | 2001-10-18 | California Inst Of Techn | Enzymvermittelte Modifikation von Fibrin für das Gewebs-Engineering |
| US6181909B1 (en) * | 1997-07-22 | 2001-01-30 | Educational Testing Service | System and method for computer-based automatic essay scoring |
| US6269368B1 (en) * | 1997-10-17 | 2001-07-31 | Textwise Llc | Information retrieval using dynamic evidence combination |
| DE69841850D1 (de) * | 1997-12-02 | 2010-09-30 | Artecel Sciences Inc | Differenzierung in osteoblasten der fettgewebe-stromalen zellen und ihre verwendungen |
| GB9801061D0 (en) | 1998-01-20 | 1998-03-18 | Univ Nottingham | Patterning technique |
| SE519827C2 (sv) * | 1998-03-30 | 2003-04-15 | Viranative Ab | Näringsmedium innehållande metionin samt användning av detta |
| US6548048B1 (en) * | 1998-04-28 | 2003-04-15 | Amersham Health As | Lipopeptide stabilized microbubbles as diagnostic/therapeutic agents |
| GB9809084D0 (en) | 1998-04-28 | 1998-06-24 | Nycomed Imaging As | Improvements in or relating to diagnostic/therapeutic agents |
| US7601685B2 (en) * | 1998-08-27 | 2009-10-13 | Eidgenossische Technische Hochschule Zurich | Growth factor modified protein matrices for tissue engineering |
| DE69936212T2 (de) | 1998-09-04 | 2008-01-24 | Scios Inc., Sunnyvale | Hydrogelzusammensetzungen mit kontrollierter Freigabe für die Verabreichung von Wachstumsfaktoren |
| CA2277732A1 (en) * | 1998-09-15 | 2000-03-15 | Isotis B.V. | Method for coating medical implants |
| US6114038A (en) * | 1998-11-10 | 2000-09-05 | Biocrystal Ltd. | Functionalized nanocrystals and their use in detection systems |
| AU773914B2 (en) | 1999-02-01 | 2004-06-10 | Eidgenossische Technische Hochschule Zurich | Biomaterials formed by nucleophilic addition reaction to conjugated unsaturated groups |
| WO2000045831A1 (en) | 1999-02-02 | 2000-08-10 | Thomas Jefferson University | Peptides modulating activities of heparin, other glycosaminoglycans or proteoglycans |
| WO2000052145A2 (en) | 1999-03-02 | 2000-09-08 | University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus | Embryonic or stem-like cell lines produced by cross species nuclear transplantation |
| US6473730B1 (en) * | 1999-04-12 | 2002-10-29 | The Trustees Of Columbia University In The City Of New York | Method and system for topical segmentation, segment significance and segment function |
| ATE314863T1 (de) | 1999-04-22 | 2006-02-15 | Eidgenoess Tech Hochschule | Kontrollierte abgabe der wachstumsfaktoren von heparin enthaltenden matrizen |
| US20090087878A9 (en) * | 1999-05-06 | 2009-04-02 | La Rosa Thomas J | Nucleic acid molecules associated with plants |
| IL147179A0 (en) | 1999-06-30 | 2002-08-14 | Advanced Cell Tech Inc | Cytoplasmic transfer to de-differentiate recipient cells |
| US6444723B1 (en) * | 1999-11-10 | 2002-09-03 | The United States Of America As Represented By The Secretary Of Commerce | Crosslinked micellar gel composition |
| ES2304359T3 (es) | 1999-12-28 | 2008-10-16 | The Regents Of The University Of Michigan | Procedimiento de formacion ex vivo de hueso de mamiferos y usos del mismo. |
| WO2001055309A2 (en) | 2000-01-31 | 2001-08-02 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
| US20030050231A1 (en) * | 2000-01-31 | 2003-03-13 | Rosen Craig A. | Nucleic acids, proteins, and antibodies |
| ATE244027T1 (de) | 2000-02-04 | 2003-07-15 | Isotis Nv | Proteinbeschichtung |
| US6689165B2 (en) * | 2000-03-31 | 2004-02-10 | Board Of Supervisors Of Louisana State University And Agricultural And Mechanical College | Surface modifications for enhanced epithelialization |
| JP2003531930A (ja) * | 2000-04-28 | 2003-10-28 | ユニバーシティ・カレッジ・ダブリン | 両親媒性大環状誘導体およびそれらの類似体 |
| WO2001086489A2 (en) * | 2000-05-11 | 2001-11-15 | University Of Southern California | Discourse parsing and summarization |
| WO2002020723A2 (en) | 2000-09-08 | 2002-03-14 | Board Of Regents, The University Of Texas System | Compositions and methods for targeting peptides in humans in vivo |
| CA2426692C (en) * | 2000-10-19 | 2011-01-25 | Eidgenossische Technische Hochschule Zurich | Block copolymers for multifunctional self-assembled systems |
| CA2431552A1 (en) | 2000-11-06 | 2002-05-16 | Thrasos, Inc. | Screening methods for bone morphogenetic mimetics |
| CA2436740A1 (en) * | 2001-01-23 | 2002-08-01 | Educational Testing Service | Methods for automated essay analysis |
| WO2002062969A2 (en) | 2001-02-06 | 2002-08-15 | Massachusetts Institute Of Technology | Cellular reprogramming in peptide hydrogel and uses thereof |
| US7449180B2 (en) * | 2001-02-06 | 2008-11-11 | John Kisiday | Macroscopic scaffold containing amphiphilic peptides encapsulating cells |
| WO2003006043A1 (en) * | 2001-07-10 | 2003-01-23 | Massachusetts Institute Of Technology | Surfactant peptide nanostructures, and uses thereof |
| AU2002361601A1 (en) | 2001-11-06 | 2003-05-19 | Mark C. Fishman | Stem and progenitor cell capture for tissue regeneration |
| AU2002365162A1 (en) | 2001-11-14 | 2003-07-09 | Northwestern University | Self-assembly and mineralization of peptide-amphiphile nanofibers |
| AU2003215280A1 (en) | 2002-02-15 | 2003-09-09 | Northwestern University | Self-assembly of peptide-amphiphile nanofibers under physiological conditions |
| WO2003084980A2 (en) | 2002-04-02 | 2003-10-16 | Northwestern University | Peptide amphiphile solutions and self assembled peptide nanofiber networks |
| AU2003226428A1 (en) * | 2002-04-18 | 2003-11-03 | Northwestern University | Encapsulation of nanotubes via self-assembled nanostructures |
| JP2005185101A (ja) * | 2002-05-30 | 2005-07-14 | National Institute Of Agrobiological Sciences | 植物の全長ｃＤＮＡおよびその利用 |
| AU2003279912A1 (en) | 2002-06-27 | 2004-01-19 | Northwestern University | Peptide rod amphiphiles and self-assembly of same |
| AU2003285853A1 (en) | 2002-07-23 | 2004-04-30 | Northwestern University | Self-assembled hybrid compositions and method of making, using and ordering same |
| US7534761B1 (en) * | 2002-08-21 | 2009-05-19 | North Western University | Charged peptide-amphiphile solutions and self-assembled peptide nanofiber networks formed therefrom |
| WO2004106359A2 (en) | 2002-09-23 | 2004-12-09 | Northwestern University | Self-assembled peptide-amphiphiles & self-assembled peptide nanofiber networks presenting multiple signals |
| US7135027B2 (en) * | 2002-10-04 | 2006-11-14 | Baxter International, Inc. | Devices and methods for mixing and extruding medically useful compositions |
| US7554021B2 (en) * | 2002-11-12 | 2009-06-30 | Northwestern University | Composition and method for self-assembly and mineralization of peptide amphiphiles |
| WO2005003292A2 (en) | 2002-11-12 | 2005-01-13 | Northwestern University | Composition and method for self-assembly and mineralization of peptide amphiphiles |
| WO2004046167A2 (en) | 2002-11-14 | 2004-06-03 | Northwestern University | Synthesis and self-assembly of abc triblock bola peptide |
| US7390526B2 (en) * | 2003-02-11 | 2008-06-24 | Northwestern University | Methods and materials for nanocrystalline surface coatings and attachment of peptide amphiphile nanofibers thereon |
| US7259140B2 (en) | 2003-03-28 | 2007-08-21 | Thomas Jefferson University | Heparin-binding peptides and uses thereof |
| US20070141101A1 (en) | 2003-04-10 | 2007-06-21 | The Trustees Of Boston University | Method for stimulating angiogenesis and wound healing |
| AU2004297211A1 (en) * | 2003-12-05 | 2005-06-23 | Northwestern University | Branched peptide amphiphiles, related epitope compounds and self assembled structures thereof |
| EP1696945B1 (en) | 2003-12-05 | 2012-01-18 | Northwestern University | Self-assembling peptide amphiphiles and related methods for growth factor delivery |
| US20050214257A1 (en) * | 2003-12-23 | 2005-09-29 | Northwestern University | Compositions and methods for controlling stem cell and tumor cell differentiation, growth, and formation |
| AU2005229008B2 (en) * | 2004-03-23 | 2011-03-24 | Lifeline Nutraceuticals Corporation | Compositions and method for alleviating inflammation and oxidative stress in a mammal |
| MX2007008826A (es) | 2005-01-21 | 2007-11-15 | Univ Northwestern | Metodos y composiciones para encapsulacion de celulas. |
| AU2006206272A1 (en) * | 2005-01-21 | 2006-07-27 | Alza Corporation | Therapeutic peptide formulations for coating microneedles with improved stabitity containing at least one counterion |
| US7851445B2 (en) * | 2005-03-04 | 2010-12-14 | Northwestern University | Angiogenic heparin-binding epitopes, peptide amphiphiles, self-assembled compositions and related methods of use |
| DK1891104T3 (da) * | 2005-05-04 | 2009-11-30 | Lonza Ag | Fastfasebundet thmosin-alfa1 og syntese deraf |
| CN1915438A (zh) * | 2006-07-27 | 2007-02-21 | 华中科技大学同济医学院附属协和医院 | 新型多肽神经组织工程支架材料及其制备方法和应用 |
| US8114835B2 (en) * | 2006-11-09 | 2012-02-14 | Northwestern University | Self-assembling peptide amphiphiles for tissue engineering |
| US8114834B2 (en) * | 2006-11-09 | 2012-02-14 | Northwestern University | Self-assembling peptide amphiphiles |
| WO2008101104A2 (en) * | 2007-02-14 | 2008-08-21 | Northwestern University | Aligned nanofibers and related methods of use |
| US8076295B2 (en) | 2007-04-17 | 2011-12-13 | Nanotope, Inc. | Peptide amphiphiles having improved solubility and methods of using same |
| WO2009026233A2 (en) * | 2007-08-17 | 2009-02-26 | Northwestern University | Self assembling peptide systems and methods |
-
2008
- 2008-04-16 US US12/104,407 patent/US8076295B2/en not_active Expired - Fee Related
- 2008-04-17 EP EP08746046A patent/EP2146734A4/en not_active Withdrawn
- 2008-04-17 WO PCT/US2008/060559 patent/WO2008131052A2/en not_active Ceased
- 2008-04-17 JP JP2010504238A patent/JP2010524958A/ja active Pending
- 2008-04-17 AU AU2008242940A patent/AU2008242940A1/en not_active Abandoned
- 2008-04-17 CN CN200880020680A patent/CN101848722A/zh active Pending
- 2008-04-17 KR KR1020097023819A patent/KR20100021567A/ko not_active Withdrawn
- 2008-04-17 CA CA2690772A patent/CA2690772A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008131052A9 (en) | 2010-02-25 |
| WO2008131052A2 (en) | 2008-10-30 |
| AU2008242940A1 (en) | 2008-10-30 |
| EP2146734A2 (en) | 2010-01-27 |
| EP2146734A4 (en) | 2010-12-15 |
| US8076295B2 (en) | 2011-12-13 |
| JP2010524958A (ja) | 2010-07-22 |
| CN101848722A (zh) | 2010-09-29 |
| KR20100021567A (ko) | 2010-02-25 |
| US20090042804A1 (en) | 2009-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8076295B2 (en) | Peptide amphiphiles having improved solubility and methods of using same | |
| US8748569B2 (en) | Peptide amphiphiles and methods to electrostatically control bioactivity of the ikvav peptide epitope | |
| Yadav et al. | Short to ultrashort peptide-based hydrogels as a platform for biomedical applications | |
| EP1696945B1 (en) | Self-assembling peptide amphiphiles and related methods for growth factor delivery | |
| Webber et al. | Emerging peptide nanomedicine to regenerate tissues and organs | |
| US7452679B2 (en) | Branched peptide amphiphiles, related epitope compounds and self assembled structures thereof | |
| EP2560689B1 (en) | Novel self-assembling peptides and their use in the formation of hydrogels | |
| US20150087597A1 (en) | Polypeptides and methods of use | |
| KR20140015149A (ko) | Ｒｇｄ 바인딩 부위에 대한 세포 부착의 저해 또는 진단제 또는 치료제의 유도를 위한 조성물 및 방법 | |
| US20180030093A1 (en) | Self-assembling ultrashort aliphatic cyclic peptides for biomedical applications | |
| Kumar et al. | Self-assembling peptides: implications for patenting in drug delivery and tissue engineering | |
| US20150238431A1 (en) | Icam-1 targeting elps | |
| Boruah et al. | Advances in hybrid peptide-based self-assembly systems and their applications | |
| PT1808179E (pt) | Utilização de hsp20 para promoção da cicatrização de feridas e/ou redução da formação de cicatriz | |
| Eichler | Self-Assembling Peptides as |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20130417 |